Adapt+
Contour propagation for adaptive radiotherapy
Software · HybridCompany source
Company profile
About MVision AI
MVision AI is a health-tech company that develops AI-powered solutions for radiotherapy workflows, serving hospitals and cancer centres globally. Founded in 2017 by a team of two software engineers, a medical physicist, and an AI research scientist, the company is headquartered in Helsinki, Finland, with operations in the United States. MVision AI's flagship product, Contour+, is deployed across EMEA, APAC, and the Americas. The company's comprehensive Workspace+ platform unifies contouring, synthetic imaging, dose prediction, and contour propagation in one secure environment, designed for seamless integration with existing treatment planning systems. The GBS™ (Guideline-Based Segmentation) solution combines Contour+, Guide, and Verify to standardise contours, reduce variability, and strengthen contouring expertise through training and assessment. MVision AI's solutions are clinically evaluated and designed to automate repetitive tasks while keeping clinicians in control, reducing manual work time by up to 95% and increasing consistency by an average of 20%. The company has processed over 100,000 total scans, with 50,000 scans handled in the past year. Ranked #16 in Deloitte Fast 50 Finland, MVision AI serves radiotherapy departments, oncology clinics, and cancer centres worldwide through a global network of distributors across Asia, Middle East, Africa, Europe, and Latin America.
Company description MVision AI official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at MVision AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- Oncology
- Radiotherapy treatment planning
Who it serves
- Cancer centres
- Hospitals
- Oncology clinics
- Radiotherapy departments
Deployment & integration
Hybrid deployment with recorded integration context.
Recorded integration context: Azure AD, DICOM networking, LDAP/Active Directory, Treatment Planning Systems (TPS).
Geographic context
MarketsAmericas · APAC · Australia · Belgium · Cyprus · Eastern Europe · EMEA · France · Greece · Ireland · Italy · Japan · Latin America · Malta · New Zealand · Nordic countries · South Africa · South Korea · Spain · Switzerland · Turkey · UAE · UK
Company sourceOfficial website
Company milestones
Platform expansion
Ranked #16 in Deloitte Fast 50 Finland. Expanded Workspace+ platform with multiple modules (Contour+, Dose+, Image+, Adapt+). Established global distributor network across 20+ countries.
Partnerships
Recorded partners
- Global distributor network across 20+ countries
- Hospital and cancer centre partnerships in EMEA, APAC, Americas
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Contour+
AI-powered automated contouring for radiotherapy
Software · HybridCompany source
Dose+
Personalised AI dose prediction for radiotherapy
Software · HybridCompany source
GBS™ Solution (Guideline-Based Segmentation)
Guideline-based segmentation for greater consistency in radiotherapy
Software · HybridCompany source
Guide
Training and guidance for guideline-based contouring
Software · HybridCompany source
Image+
Synthetic imaging for radiotherapy workflows
Software · HybridCompany source
Verify
Quality assurance for radiotherapy contours
Software · HybridCompany source
Workspace+
Unified AI platform for radiotherapy workflows
Platform · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Towards rapid and efficient simulation-free radiotherapy: MR guided adaptive prostate radiotherapy on the MR-Linac using diagnostic MRI reference planning.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · Oct 1, 2025
Multicentre evaluation of deep learning CT autosegmentation of the head and neck region for radiotherapy.NPJ digital medicine · May 27, 2025
Design and evaluation of a deep learning-based automatic segmentation of maxillary and mandibular substructures using a 3D U-Net.Clinical and translational radiation oncology · Jul 1, 2024
Organ-sparing techniques and dose-volume constrains used in breast cancer radiation therapy - Results from European and Latin American surveys.Clinical and translational radiation oncology · May 1, 2024
Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group.Frontiers in oncology · Jan 1, 2024
Autosegmentation based on different-sized training datasets of consistently-curated volumes and impact on rectal contours in prostate cancer radiation therapy.Physics and imaging in radiation oncology · Apr 1, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Dose+ (1.0)K250064 · 510k · Sep 4, 2025
Contour+ (MVision AI Segmentation)K241490 · 510k · Oct 18, 2024
MVision AI SegmentationK212915 · 510k · May 3, 2022
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Manual work time saving up to 95%
Radiotherapy treatment preparation and contouring workflows
20% average increase in consistency
Contouring and treatment planning standardisation
100,000+ total scans processed
Platform usage across global customer base
50,000 scans in past year
Recent platform activity
Global radiotherapy departments
Automated contouring and radiotherapy workflow optimization
Up to 95% manual work time saving and 20% increase in consistency on average
Multiple facilities
AI-powered radiotherapy preparation across EMEA, APAC, and Americas
100k total scans handled, 50k scans processed in the past year
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from MVision AI
Recent articles published on MVision AI's official website.
AI in Clinical Radiotherapy: Insights from Michael Roche at CUH/UCC Cancer Centre
Read on MVision AICancer care and radiotherapy in the UK
Read on MVision AIDr. Baozhou Sun of Baylor College of Medicine: Building Trust in AI Across the Radiotherapy Workflow
Read on MVision AIAI-Driven Workflow in Radiotherapy: Insights from Clinical Experts at MVZ Strahlentherapie Singen-Friedrichshafen
Read on MVision AIMeeting Global Radiotherapy Demand with AI
Read on MVision AI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.